James A. Schoeneck
President and Chief Executive Officer
Mr. Schoeneck joined Depomed as president and chief executive officer in April 2011 and has served on the company’s Board of Directors since December 2007. From 2005 until joining Depomed, Mr. Schoeneck was chief executive officer of BrainCells Inc., a private biopharmaceutical company. Prior to joining BrainCells, he served as chief executive officer of ActivX BioSciences, a development stage biotechnology company. Mr. Schoeneck's broad pharmaceutical experience also includes three years as president and chief executive officer of Prometheus Laboratories Inc., where he led the company to profitability and rapid revenue growth, increasing annual sales from $6 million to over $70 million. Under Mr. Schoeneck's leadership, Prometheus was recognized as the third fastest-growing private company in America by Inc. magazine. Prior to Prometheus, Mr. Schoeneck spent three years at Centocor, Inc., where he led the development of Centocor's commercial capabilities, growing his team from three people to almost 500 in less than three years. His group launched Remicade®, which has become the world's third largest selling pharmaceutical product, with over $8 billion in sales in 2012. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck serves as a member of the board of directors at Fibrogen, Inc, and AnaptysBio, Inc., a privately-held biotechnology company focused on inflammation and immuno-oncology drug development. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University.